Remikiren
![]() | |
| Systematic (IUPAC) name | |
|---|---|
|
(2S)-2-[(2R)-2-benzyl-3-(2-methylpropane-2-sulfonyl)propanamido]-N-[(2R,3S,4R)-1-cyclohexyl-4-cyclopropyl-3,4-dihydroxybutan-2-yl]-3-(1H-imidazol-4-yl)propanamide | |
| Clinical data | |
| Legal status |
|
| Identifiers | |
| CAS Number |
126222-34-2 |
| ATC code | C09XA01 (WHO) |
| PubChem | CID 6324659 |
| DrugBank |
DB00212 |
| ChemSpider |
4884377 |
| UNII |
LC7FBL96A4 |
| KEGG |
D09038 |
| ChEMBL |
CHEMBL31601 |
| Chemical data | |
| Formula | C33H50N4O6S |
| Molar mass | 630.839 g/mol |
| |
| |
| (verify) | |
Remikiren is a renin inhibitor under development for the treatment of hypertension (high blood pressure). It was first developed by Hoffmann–La Roche in 1996.[1]
References
- ↑ Richter WF, Whitby BR, Chou RC (1996). "Distribution of remikiren, a potent orally active inhibitor of human renin, in laboratory animals". Xenobiotica 26 (3): 243–54. doi:10.3109/00498259609046705. PMID 8730917.
| ||||||||||||||||||
This article is issued from Wikipedia - version of the Saturday, April 02, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.
